Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6% – Here’s What Happened

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded down 14.6% on Tuesday . The company traded as low as C$1.24 and last traded at C$1.29. 551,069 shares changed hands during mid-day trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Stock Performance

The firm has a market capitalization of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The firm has a 50-day moving average price of C$1.50 and a two-hundred day moving average price of C$1.64.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. On average, analysts forecast that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.